摘要
卵巢癌初始治疗对手术和化疗药物反应良好,但肿瘤复发或化疗耐药往往会导致治疗失败。内分泌治疗为复发性或耐药性卵巢癌患者带来了新的治疗选择。内分泌药物具有不良反应少、耐受性好、治疗费用低等优势。与单独用药相比,联合分子靶向药物、抗血管生成药物以及化疗药物等,可能会发挥协同作用和药物增敏作用,提高内分泌治疗的效果。本文主要对内分泌治疗在卵巢癌中的研究进展进行综述,为卵巢癌的内分泌治疗提供理论依据。
Initial treatment for ovarian cancer responds well to surgery and chemotherapy drugs,but tumor recurrence or chemotherapy resistance often leads to treatment failure.Endocrine therapy offers new treatment options for patients with relapsed or drug-resistant ovarian cancer.Endocrine drugs have the advantages of less adverse reactions,good tolerance and low treatment cost.Compared with single drugs,combination of molecular targeted drugs,anti-angiogenic drugs and chemotherapy drugs may exert synergistic effects and drug sensitization to improve the effect of endocrine therapy.This article mainly reviewed the research progress of endocrine therapy in ovarian cancer,and provided theoretical basis for endocrine therapy in ovarian cancer.
作者
王喆
张颐
WANG Zhe;ZHANG Yi(Department of Gynecology,First Affiliated Hospital of China Medical University,Shenyang,Liaoning,110001)
出处
《实用临床医药杂志》
CAS
2021年第13期115-118,128,共5页
Journal of Clinical Medicine in Practice
基金
国家重点研发计划重点专项(2018YFC1311600)
辽宁省中央引导地方科技发展专项(2019JH6/10400006)
中国医科大学2019年度临床医学培育学科支持计划(妇产科学-机器人)
中国医科大学国际水平项目(2019年)。
关键词
卵巢癌
内分泌治疗
联合治疗
耐受
化疗
ovarian cancer
endocrine therapy
combination therapy
tolerance
chemotherapy
